Trial · NCT07882810
Haptic-Assisted Virtual Reality Upper-Limb Rehabilitation After Intracerebral Haemorrhage
NCT07882810, Not applicable, Not yet recruiting, University Medical Centre Maribor
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Haptic-Assisted Virtual Reality Upper-Limb Rehabilitation After Intracerebral Haemorrhage. Trials, record NCT07882810. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07882810
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Haptic-Assisted Virtual Reality Upper-Limb Rehabilitation After Intracerebral Haemorrhage
- NCT number
- NCT07882810
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 100 participants, estimated
- Lead sponsor
- University Medical Centre Maribor
- Conditions
- Intracerebral Hemorrhage, Hemorrhagic Stroke, Paresis
- Interventions
- Haptic-assisted virtual reality training (Bimeo PRO), Conventional rehabilitation
- First posted
- 2026-10-20
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Fugl-Meyer Assessment - Upper Extremity (FMA-UE) motor score | Baseline and after the 2-week intervention period | FMA-UE motor score, 0-66; higher scores indicate better upper-limb motor function. |
| Secondary | Change in Wolf Motor Function Test (WMFT) | Baseline and after the 2-week intervention period | WMFT performance time and functional ability scale (0-5 per task; higher functional ability scores indicate better function; shorter times indicate better performance). |
| Secondary | Change in grip strength | Baseline and after the 2-week intervention period | Maximal grip strength of the affected hand measured with a hand-held dynamometer, in kilograms. |
| Secondary | Change in neurological deficit (NIHSS) | Baseline and after the 2-week intervention period | National Institutes of Health Stroke Scale score (0-42; higher scores indicate more severe deficit). |
| Secondary | Change in disability (modified Rankin Scale) | Baseline and after the 2-week intervention period | mRS score (0 = no symptoms to 6 = death; higher scores indicate worse outcome). |
| Secondary | Adherence to the rehabilitation programme | During the 2-week intervention period | Number and proportion of planned sessions and planned VR minutes completed. |
| Secondary | Tolerability | During the 2-week intervention period | Proportion of sessions shortened or discontinued because of fatigue, pain, dizziness, discomfort or other intolerance. |
| Secondary | Adverse events | During the 2-week intervention period | Number and type of adverse events and serious adverse events, including fatigue, transient pain, dizziness and falls. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07882810
GET https://conductscience.org/api/trials/v1/NCT07882810/registered